Placing PRINCE in perspective

JAMA

Volumn 286, Issue 1, 2001, Pages 91-93

  Simpson R J , Jr ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PRAVASTATIN;

ANTIINFLAMMATORY ACTIVITY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SCREENING; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL;

EID: 0035806598     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.1.91     Document Type: Editorial

References (22)

1. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation CRP Evaluation (PRINCE): A randomized trial cohort study
2. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease meta-analyses of prospective studies
3. Mechanisms of disease: Atherosclerosis, an inflammatory disease
4. Elevated levels of intedeukin-6 in unstable angina
5. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
6. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsbur Cohort Study, 1984 to 1992
7. Direct proinflammatory effect of C-reactive protein on human endothelial cells
8. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
9. Elevated C-reactive protein levels in overweight and obese adults
10. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
11. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
12. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
13. Infections, inflammation, and the risk of coronary heart disease
14. Production of C-reactive protein and risk of coronary events in stable and unstable angina
15. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
16. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity C-reactive protein levels
17. The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design
18. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. PRINCE's prospects: Statins, inflammation, and coronary risk
21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
22. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age